PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...
SB Nation on MSN14h
49ers looking to earn big incentives, hit key milestones against CardinalsThe San Francisco 49ers may not have any opportunity to play their way into the playoffs in their Week 18 matchup against the ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will be paying its dividend of $0.43 on the 7th of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback